ANGO
AngioDynamics, Inc. · Healthcare · Medical - Instruments & Supplies
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +5.0% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | -1 | 44.02K | $609,566 | n/a | −1 |
| Q2 2026 | 72 | +3 | 20.49M | $266.54M | +7 | −4 |
| Q1 2026 | 71 | -1 | 21.06M | $239.47M | +4 | −5 |
| Q4 2025 | 72 | 0 | 22.40M | $287.62M | +1 | −1 |
| Q3 2025 | 18 | 0 | 15.02M | $167.73M | n/a | n/a |
| Q2 2025 | 15 | -1 | 13.76M | $136.51M | n/a | −1 |
| Q1 2025 | 13 | +2 | 6.65M | $62.49M | +2 | n/a |
| Q4 2024 | 11 | 0 | 7.29M | $66.82M | n/a | n/a |
| Q3 2024 | 10 | 0 | 5.47M | $42.55M | n/a | n/a |
| Q2 2024 | 10 | n/a | 5.27M | $31.86M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 3.47M | -1.6% | $38.81M | 0.0% | ▼ Trim | 2 | SEC ↗ ×7 |
| 2 | Point72 Asset Management ✦ | 2.56M | +31.3% | $28.58M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passive) | 2.36M | -5.0% | $26.41M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 4 | Millennium Management ✦ | 1.79M | +28.1% | $20.03M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 976.65K | -0.1% | $10.91M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passive) | 956.89K | +0.4% | $10.69M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 933.38K | -12.2% | $10.43M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 8 | Arrowstreet Capital ✦ | 556.59K | -4.6% | $6.22M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 9 | Marshall Wace ✦ | 338.15K | -16.7% | $3.78M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 10 | Goldman Sachs Group ✦ | 270.12K | n/a | $3.02M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Morgan Stanley ✦ | 238.78K | n/a | $2.67M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 12 | Adage Capital Partners ✦ | 150.00K | +50.0% | $1.68M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 140.73K | +200.0% | $1.57M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | Fidelity (FMR) ✦ | 98.09K | +14.3% | $1.10M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 15 | AQR Capital Management ✦ | 69.89K | +1.0% | $780,704 | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 16 | T. Rowe Price ✦ | 42.03K | +3.3% | $470,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | JPMorgan Chase ✦ | 33.83K | n/a | $377,836 | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 18 | D. E. Shaw & Co. ✦ | 19.54K | -70.1% | $218,273 | 0.0% | ▼ Trim | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 145 holders, 38.52M shares, $430.26M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.